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Key points: 
 
• High-risk SMM patients’ immune status is mildly impaired as compared to age-
matched healthy individuals 
• High-risk SMM patients can be effectively immune modulated by lenalidomide 
even when combined with low-dose dexamethasone 
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Abstract 
 There is significant interest in immunotherapy to treat high-risk smoldering 
multiple myeloma (SMM), but no available data on the immune status of this particular 
disease-stage. Such information is important to understand the interplay between 
immune-surveillance and disease transformation, but also to define if patients with 
high-risk SMM might benefit from immunotherapy. Here, we have characterized T-
lymphocytes (including CD4, CD8, TCRγδ, and Tregs), NK- and dendritic-cells from 31 
high-risk SMM patients included in the treatment arm of the Quiredex trial, and with 
longitudinal peripheral blood samples at baseline, after 3 and 9 cycles of 
lenalidomide/dexamethasone (LenDex). High-risk SMM patients showed at baseline 
decreased expression of activation-(CD25/CD28/CD54), Th1-(CD195/IFN-γ/TNF-α/IL-
2), and proliferation-related markers (CD119/CD120b) as compared to age-matched 
healthy individuals. However, LenDex was able to restore the normal expression levels 
for those markers, and induced a marked shift in T-lymphocytes and NK-cells 
phenotype. Accordingly, high-risk SMM patients treated with LenDex showed higher 
numbers of functionally active T-lymphocytes. Altogether, our results indicate that high-
risk SMM patients have an impaired immune system that could be re-activated by the 
immunomodulatory effects of lenalidomide even when combined with low-dose 
dexamethasone, and support the value of therapeutic immunomodulation to delay the 
progression to MM.     
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Introduction 
 Multiple myeloma (MM) is an incurable plasma cell (PC) malignancy 
characterized by preceding benign stages termed as monoclonal gammopathy of 
undetermined significance (MGUS) or smoldering MM (SMM). Interestingly, no major 
differences have been described for the genetic and phenotypic profiles of clonal PCs 
during disease evolution from MGUS to SMM and treatment-requiring MM.1-8 In 
contrast, an intrinsic relation between a progressively impaired immune system and 
disease progression has been suggested 9,10 and in fact, one of the risk factors that 
predicts transformation of SMM into treatment-requiring MM is the presence of immune 
paresis.11 Accordingly, extensive characterization of bone marrow (BM) and peripheral 
blood (PB) samples from MGUS and MM patients has revealed that while immune 
effector cells remain functional in the former, T-lymphocytes and NK-cells from newly-
diagnosed and relapsed MM are unable to produce a tumor-specific immune response 
due to i) cytokine production by clonal PCs (e.g.: transforming growth factor β) 12, ii) T-
cell exhaustion  and anergy 13,14, or iii) inhibitory signaling through co-expression of PD-
1 and PD-L1 in effector and tumor cells, respectively.15,16 However, it remains unclear 
whether the quantitative and functional immune deregulation typically observed in MM 
is a cause or consequence of the increasing tumor burden.10 Because immune 
modulatory drugs (IMiDs) and novel monoclonal antibodies (e.g.: anti-CD38 and anti-
SLAMF7) rely on the activity of T-lymphocytes and NK-cells 17, such impaired immune 
system may represent a barrier for immunotherapy in active disease but not in 
preceding SMM, for which immune-therapeutic strategies aiming at preventing disease 
progression would be effective with the help of functionally active T-lymphocytes and 
NK-cells. Unfortunately, there is virtually no data on the immune status of patients with 
SMM nor if it could be therapeutically modulated (e.g.: using IMiDs); such information 
would be important to further understand the interplay between immune surveillance 
and disease transformation, as well as to define if patients with SMM might benefit from 
immune therapeutic strategies. 
 The interest in SMM has significantly increased in recent years due to both the 
identification of well-defined patient-subgroups with different risk of progression 11,18, 
and to the demonstration of the potential benefit in time-to-progression (TTP) and 
overall survival (OS) of treating high-risk SMM patients with lenalidomide plus low-dose 
dexamethasone.19 Noteworthy, a recent update of this trial has shown that even though 
a significant fraction of patients remained with detectable disease after therapy (i.e.: 
less than CR), only 14 out of 57 (25%) patients randomized to receive treatment have 
progressed so far 20; hence, it could be hypothesized that in addition to the direct tumor 
reduction induced by lenalidomide plus dexamethasone (LenDex), other factors such 
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as immune surveillance might play a role in delaying tumor progression. However, this 
has never been demonstrated. Furthermore, the combination used in the Quiredex trial 
includes the potential antagonist effects of the immune modulatory lenalidomide vs. the 
immune suppressive dexamethasone 21-25; accordingly, such potentially antagonist 
combination may represent a dilemma in the design of clinical trials investigating 
preemptive therapy in high-risk SMM.26  
 Here, we have analyzed the phenotypic profile of T-lymphocytes, NK-cells and 
dendritic cells (DCs) in high-risk SMM patients enrolled in the Quiredex trial, and 
compared them against age-matched healthy individuals to determine the immune 
status in high-risk SMM. Afterwards, we monitored such patients after 3 and 9 cycles of 
LenDex induction to evaluate the role of T-lymphocyte and NK-cell functionality in 
delaying disease progression into symptomatic MM. Finally, we compared the immune 
profile of both cell populations during maintenance with lenalidomide as single-agent to 
measure the potential antagonist effect of dexamethasone.  
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Patients and Methods 
Study design. In this pre-planned exploratory analysis, we evaluated the 
immunophenotypic profile of T-lymphocytes and NK-cells on a total of 119 PB samples 
from 31 of the 57 high-risk SMM patients allocated into the treatment arm of the 
Quiredex trial, and for which longitudinal samples were available at baseline, after 3 
cycles of LenDex, at the end of induction therapy, and during maintenance with 
lenalidomide at least 3 months after dexamethasone discontinuation (the later analysis 
being performed in 13 of the 31 patients). The criteria for patient inclusion and the 
design of the Quiredex trial have been described elsewhere 19; briefly, high-risk SMM 
was defined based on the presence of at least 2 of the 3 following criteria: BM PC 
infiltration ≥10%; high M-component (IgG≥30g/L or IgA≥20g/L or B-J Protein>1g/24h) 
18; or ≥95% clonal PCs from total BM PCs plus immune paresis.11 High-risk SMM 
patients were treated with an induction phase of 9 four-week cycles of LenDex followed 
by maintenance with lenalidomide; maintenance therapy was initially given until 
disease progression, but a protocol amendment limited the total duration of treatment 
(induction plus maintenance) to 2 years.19 A total of 10 healthy donors aged over 60 
years were also studied and used as normal reference. All control and patient samples 
were collected after informed consent was given by each individual, according to the 
local ethical committees and the Helsinki Declaration. Baseline demographic and 
disease characteristics of high-risk SMM patients are summarized in Table 1. 
 
Immunophenotypic protein expression profile (iPEP) of T-lymphocytes, NK-cells 
and DCs. We evaluated by multiparameter flow cytometry a total of 30 different 
markers distributed across 4-color monoclonal antibody combinations in PB T-
lymphocytes and NK-cells (Supplementary Table 1). Each combination included either 
CD4 plus CD8 to identify helper and cytotoxic T-lymphocytes, or CD3 plus CD56 to 
identify total T-lymphocytes plus CD56dim (cytotoxic) and CD56bright (immune regulator) 
NK-cells (Supplementary Table 2). A total of 63 phenotypic parameters were evaluated 
in each patient sample. EDTA-anticoagulated PB samples from each subject were 
immunophenotyped during the first 24h after extraction using a direct 
immunofluorescence technique to evaluate surface antigen expression. For 
intracellular cytokine staining, heparin-anticoagulated PB samples diluted in RPMI-
1640 with L-Glutamine (1:1 vol:vol) were cultured during 4 hours at 37°C in a 5% CO2-
humidified atmosphere in the presence of PMA (25ng/mL) and ionomicin (0.5mg/m) 
with or without 10 µg/mL of brefeldinA (used as negative control). Simultaneous 
staining for intracytoplasmatic IFN-γ, TNF-α, IL-2 or CD40L and surface antigens was 
performed by use of the IntraStain Fixation and Permeabilization kit (Dako 
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Cytomation). Regulatory T cells (T-regs) were enumerated using the following 
combination of markers: CD25-FITC / CD127-PE / CD4-PerCPCy5.5 / FOXP3-APC. In 
brief, 200μL of heparin anticoagulated PB samples were incubated for 15 minutes at 
room temperature and in the dark. Cells were washed in phosphate-buffered saline and 
then fixed and permeabilized with FoxP3 Staining Buffer Set (eBioscience) for FOXP3 
staining. To enumerate DCs and determine their relative distribution into myeloid, 
plasmacytoid, and tissue macrophage subpopulations, 200μl heparin anticoagulated 
PB samples were immunophenotyped using a direct immunofluorescence technique 
based on six 4-color combinations of monoclonal antibodies. All combinations included 
HLADR-FITC / CD45-PerCPCy55 and CD123-APC with a different PE-conjugated 
marker in each of the six combination: CD80, CD86, CD16, BDCA-1, CD14, and 
CD11c. Data acquisition was performed for approximately 2x105 leukocytes/tube in a 
FACSCantoII flow cytometer (BD Biosciences, San Jose, CA) and using the FACSDiva 
software (version 6.1). Monitoring of instrument performance was performed daily 
using the Cytometer Setup Tracking (CST; BD) and rainbow 8-peak beads 
(Spherotech, Inc; Lake Forest, IL) after laser stabilization, following the EuroFlow 
guidelines 27; sample acquisition was systematically performed after longitudinal 
instrument stability was confirmed. Data analysis was performed using the Infinicyt 
software (Cytognos SL, Salamanca, Spain). 
 
Cell cycle analyses. The proliferation index of CD4 and CD8 T-lymphocytes as well as 
total NK-cells was analysed using 3-color staining for nuclear DNA and two cell surface 
antigens. Briefly, 100 µL of EDTA-anticoagulated PB samples were incubated for 15 
min in the dark (room temperature) with the following combination of MoAb (FITC, PE): 
CD4, CD8, and CD3, CD56. After lysing non-nucleated red cells, the nucleated cells 
were washed and stained with 3µL/tube of DRAQ5TM (Vitro SA, Madrid, Spain). After 
another 10 min incubation, samples were immediately acquired in a FACSCantoII flow 
cytometer using the FACSDiva software program, and information on ≥105 cells 
corresponding to the whole PB cellularity was measured and stored. Data was 
analysed with the Infinicyt software and the percentage of cells in the S-phase of the 
cell cycle was calculated as described elsewhere.28 
 
Statistical analysis. The number of PB CD4 and CD8 T-lymphocytes as well as 
CD56dim and CD56bright NK-cells was recorded as absolute number of cells/μL. Antigen 
expression was defined as percentage of positive cells for markers in which two 
discrete subsets could be identified (negative vs. positive cells), or by mean 
fluorescence intensity (MFI) units for markers with a homogeneous and unimodal 
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pattern of expression. A supervised cluster analysis was performed using the 
MultiExperiment Viewer software (version 4.6.1) to compare the immunophenotypic 
protein expression profile (iPEP) obtained of high-risk SMM patients at baseline, after 3 
cycles of LenDex and at the end of induction therapy. The Pearson correlation and 
average linkage clustering were used as distance and linkage methods, respectively. 
The comparison between patients iPEP at the end of induction vs. maintenance was 
performed by principal component analysis (PCA), based on the simultaneous 
evaluation of the 63 phenotypic parameters analyzed per sample under the automated 
population separator (APS) graphical representation of the Infinicyt software. The 
Mann-Whitney U and Kruskal-Wallis H test were used to evaluate the statistical 
significance of differences observed between two or more groups, respectively. We 
used the SPSS software (version 15.0; SPSS Inc., Chicago, IL) for all statistical 
analyses. 
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Results 
The immune status of high-risk SMM patients. Patients with high-risk SMM showed 
normal absolute numbers of CD4 and CD8 T-lymphocytes as well as CD56dim and 
CD56bright NK-cells (Figure 1A). No differences were noted for the relative distribution of 
the CD4 and CD8 subsets within total T-lymphocytes, as well as for CD56dim and 
CD56bright cells within the total NK-cell compartment (Figure 1B). High-risk SMM 
patients also showed similar distribution of antigen-related maturation subsets within 
total CD4 and CD8 T-lymphocytes as compared to healthy individuals (Figure 1C). By 
contrast, there was a significant increment of TCRγδ positive T-lymphocytes (median of 
37 vs. 18 cells/µL, respectively; P =.02) as well as of Tregs (median of 1.7% vs. 0.5%, 
respectively; P =.04) in the PB of patients with high-risk SMM as compared to age-
matched healthy individuals (Figure 1D). There was a trend for lower DC counts in 
high-risk SMM patients vs. healthy individuals (P =.08; Figure 1E), and a more detailed 
analysis of the distinct subsets of DCs and tissue macrophages showed an altered 
distribution of BDCA-1 positive myeloid DCs (2% vs. 14%; P =.02) as well as tissue 
macrophages (74% vs. 47%; P =.06). Although no differences were observed for the 
absolute numbers and cellular distribution of CD4 and CD8 T-lymphocytes, significant 
differences emerged while comparing their immunophenotypic protein expression 
profile (iPEP); namely, the expression levels of activation markers such as CD25, 
CD28 and CD54 (Figure 2A) as well as Th1-related markers such as surface CD195 
and secretion of IFN-γ, TNF-α, or IL-2 (Figure 2B) were significantly inferior in T-
lymphocytes from high-risk SMM patients vs. healthy individuals. A significant down-
regulation of proliferation-related markers such as CD119 and CD120b was also noted 
among high-risk SMM patients (P <.005; data not shown), but no significant differences 
in the percentage of proliferating CD4 and CD8 T-lymphocytes (as well as NK-cells) 
were observed as compared to healthy age-matched individuals (Figure 3). 
 
Immune modulation of high-risk SMM patients with LenDex. To assess the 
combined effect of lenalidomide plus dexamethasone on T-lymphocytes and NK-cells, 
we compared the immune status of the 31 high-risk SMM patients at baseline 
(inclusion in the clinical trial) vs. after 3 and 9 cycles of LenDex. Interestingly, the 
absolute numbers of TCRγδ positive T-lymphocytes as well as the frequency of Tregs 
were further increased after 3 and 9 cycles of LenDex, respectively; conversely, CD4 
T-lymphocytes were significantly decreased at the end of induction therapy (Figure 1A). 
No significant differences were noted for the remaining cell populations including 
overall DC counts and distribution of DC subsets and tissue macrophages, nor for the 
relative distribution of the CD4/CD8 and CD56dim/CD56bright subsets within total T-
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lymphocytes and NK-cells, respectively (Figure 1B). By contrast, there was a marked 
shift on the distribution of antigen-related maturation subsets induced by LenDex, and 
reflected by a significant increase of central memory CD4 (38% vs. 52% vs. 61% at 
baseline, cycles 3 and 9 of LenDex, respectively; P <.001) and effector memory CD8 
(46% vs. 60% vs. 58% at baseline, cycles 3 and 9 of LenDex, respectively; P <.001) T-
lymphocytes (Figure 1C). Since the accumulation of antigen-experienced T-
lymphocytes is typically related to increased activation and proliferation, we then 
compared the iPEP of T-lymphocytes and NK-cells of all patient’ samples longitudinally 
collected at baseline, and after cycles 3 and 9 of LenDex (Figure 4). Accordingly, CD4 
and/or CD8 T-lymphocytes showed an increased expression of activation markers such 
as CD69, CD25, CD28, and CD54, together with an up-regulation of the Th1 related 
chemokine CCR5 (CD195) and increased cytokine production of IFNγ, TNFα, and IL-2. 
An overall analysis on total (CD3+ve) T-lymphocytes plus CD56dim and CD56bright NK-
cells showed an up-regulation of the activation marker HLA-DR (P <.001; Figure 2A), 
the ADCC associated receptor CD16 (P ≤.005), and the adhesion molecules CD11a (P 
≤.001) and CD11b (P ≤.005) after 3 and 9 courses of LenDex (data not shown). By 
contrast, no differences were observed for the expression of the lectin-like receptor 
CD94 as well as the inhibitory receptors CD158a, CD161, NKB1 and NKAT2 in the 
surface of NK-cells throughout induction therapy (data not shown). Cell cycle analysis 
(Figure 3) revealed that the percentage of cells in S-phase progressively increased 
from baseline vs. 3 and 9 cycles of LenDex for CD4 (0.03% vs. 0.07% vs. 0.12%; P 
<.001) and CD8 (0.02% vs. 0.07% vs. 0.13%; P <.001) T-lymphocytes as well as NK-
cells (0% vs. 0.09% vs. 0.11%; P <.001). Upon demonstrating the immune modulation 
of high-risk SMM throughout the 9 induction cycles of LenDex, we then investigated 
whether patients achieving at least very good partial response (≥VGRP) after 9 cycles 
of LenDex showed unique immune features at this specific time-point. Interestingly, 
patients in ≥VGPR had a trend towards lower expression of CD158a (P =.09) and the 
NKAT (P =.06) killer-immunoglobulin receptor (KIR) among total CD56dim NK-cells, 
higher expression of CD25 (P =.04), CD120b (P =.06) and CD54 (P =.08) among CD4 
T-lymphocytes, as well as higher expression of CD28 (P =.07) and CD195 (P =.01) 
among CD8 T-lymphocytes. Also, the percentage of proliferating NK-cells was 
significantly increased (P =.02) among patients in ≥VGPR. Afterwards, we investigated 
if patients with sustained disease control showed unique phenotypic features as 
compared to patients that progressed into treatment-requiring MM. With a median 
follow-up of 5-years, 19 patients remained asymptomatic whereas 12 cases 
progressed into symptomatic MM (Supplementary Figure 1), without significant 
differences in median follow-up between patients remaining asymptomatic vs. those 
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progressing into symptomatic MM. Interestingly, while at baseline only the percentage 
of CD158a positive CD56dim NK-cells significantly differed between asymptomatic and 
progressing cases (medians of 16% vs. 38%, respective; P =.02), upon therapy 
patients with sustained disease control showed significantly increased absolute 
numbers of TCRγδ positive T-lymphocytes (medians of 53 vs. 35 cells/µL; P =.03) as 
well as a higher expression of CD94 among CD56dim cytotoxic NK-cells (56% vs. 40%; 
P =.001) after LenDex treatment. In order to account for differences in baseline levels, 
we also compared median fold-change expression (from baseline to cycle 9 of LenDex) 
of each individual marker between asymptomatic vs. progressing patients. Our results 
show that CD16 fold-change expression in CD56bright NK cells (35 vs. 4; P =.05), as 
well as IL-2 (9 vs. -10.5; P =.03) and CD195 (5 vs. -3; P =.01) fold-change expression 
in CD4 T-lymphocytes was significantly increased among asymptomatic vs. 
progressing patients, respectively (Figure 5). 
 
Is dexamethasone abrogating the immune stimulatory effect of lenalidomide? To 
address the question whether dexamethasone antagonizes the immune modulatory 
properties of lenalidomide, we compared the immune profile of 13 patients with PB 
samples collected at the end of the 9 induction cycles with LenDex vs. paired samples 
obtained during maintenance (single-agent lenalidomide, and at least 3 months after 
dexamethasone discontinuation). No significant differences were observed for the 
absolute numbers of all cell populations analyzed, nor for the relative distribution of 
CD4/CD8 T-lymphocytes and CD56dim/CD56bright NK-cells, nor for the antigen-related 
maturation subset distribution of CD4 and CD8 T-lymphocytes (data not shown). 
Further comparison of patients’ iPEP at cycle 9 vs. during maintenance revealed that 
from the total 63 phenotypic parameters analyzed, only 7 were found to be differently 
expressed. Namely, the percentage of CD94 and CD154 positive T-lymphocytes, 
CD212 positive CD4 and CD8 T-lymphocytes, as well as the MFI of CD11a in T-
lymphocytes and CD56dim and CD56bright NK-cells were down-regulated during 
maintenance (data not shown). Accordingly, an overall analysis of patients’ immune 
status shows overlapping iPEP without a clear clustering of samples collected after 9 
induction cycles of LenDex (represented by circles) vs. maintenance with single-agent 
lenalidomide (represented by squares) (Figure 6).  
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Discussion 
Understanding the biologic and cellular mechanism involved in the transition 
between benign and malignant MM has become particularly important with the 
emergence of new diagnostic criteria 29 and potential benefit for early-treatment of 
SMM patients at higher risk of progression into symptomatic MM.19 However, while 
several studies have focused on the genomic characterization of SMM 1-4,6,7,30, no 
research efforts have been made to evaluate the immune system of SMM.10 Here, we 
undertook a detailed characterization of high-risk SMM patients’ immune status and 
noted a mild functional impairment as compared to age-matched healthy individuals; 
afterwards, we demonstrated that high-risk SMM patients can be effectively immune 
modulated by lenalidomide and consequently, we also showed that the immune 
modulatory effects of lenalidomide were not lost when combined with low-dose 
dexamethasone. These observations suggest that increasing numbers of functionally 
active immune cells after LenDex may have partially contributed to reduce the risk of 
transformation of high-risk SMM patients. 
Extensive studies in the BM and PB samples from patients with MGUS and 
symptomatic MM have shown that T-lymphocytes and NK-cells become quantitatively 
and functionally altered in the latter stage of the disease 31-42, thereby suggesting a 
relation between an impaired immune system and the transformation of MM. 
Conversely, we 41 and others 43 have recently shown that patients in “operational cure” 
(i.e.: >10-years progression-free survival of-therapy) have unique immune signatures 
characterized by increased numbers of effector cytotoxic CD8+ T-lymphocytes, NK 
cells, as well as B-lymphocytes and normal PCs. Because some of these patients had 
detectable residual disease, it was postulated that tumor immune surveillance, by 
functionally active cytotoxic, cells could prevent disease progression in such patients. 
When considering the natural evolution of MM, it could be hypothesized that the 
balance between immune surveillance and tumor escape should be particularly critical 
at the stage of SMM; in fact, it is well-known that the transformation of smoldering into 
symptomatic MM is characterized by a dysfunctional humoral immune response (e.g.: a 
skewed ratio of serum free light-chains 44 and immune paresis 11) but unfortunately, a 
detailed analysis of the immune status of SMM patients has never been performed. 
Here, we have demonstrated that while SMM patients at higher risk of transformation 
have normal absolute numbers of immune effector cells, CD4 and CD8 T-lymphocytes 
showed down-regulation of a selected number of activation-, Th1-, and proliferation-
related markers. Such modulation of T-lymphocytes iPEP could be potentially 
explained by the increased frequency observed for Tregs since several studies have 
shown that these are increased and functionally immunosuppressive in the PB of 
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symptomatic MM patients.45,46 Conversely, BDCA-1 positive myeloid DCs were 
decreased in patients’ PB and even though differences were not statistically significant, 
we have found similar patterns for plasmacytoid DCs and tissue macrophage 
distribution as compared to newly-diagnosed symptomatic MM.41 By contrast, no 
differences were noted in the iPEP of NK-cells from high-risk SMM patients vs. age-
matched healthy individuals. These results may be clinically relevant given the 
promising role of immune therapeutic strategies aimed at boosting immune surveillance 
and controlling disease progression (e.g.: monoclonal antibodies and checkpoint 
inhibitors). 
IMiDs such as lenalidomide have been widely adopted for the treatment of MM 
usually in combination with dexamethasone. IMiDs activity is mediated by modulating 
the substrate specificity of the E3 Ubiquitin ligase, CRL4CRBN. Thus, Lenalidomide 
treatment results in increased ubiquitinylation of the transcription factors Ikaros and 
Aiolos  and consequent altered expression of their target genes including IRF4 and IL-
2.This is thought to explain its dual mechanism of action involving both a direct anti-MM 
activity (through reduced IRF4 expression) and immune modulation (through boosted 
IL-2 production by T-lymphocytes).47,48 In addition, lenalidomide increases NK-cell 
responses by lowering its activation threshold through both CD16 and NKG2D.49 Thus, 
significant concern exists on the simultaneous use of dexamethasone with IMiDs 
because it could antagonize the immune-enhancing effect of the latter. Accordingly, it 
has been shown that dexamethasone abrogates lenalidomide induced T-lymphocyte 
production of IL-2 and NK-cell production of IFNγ and granzyme B, NK-cell receptor 
expression, and in vitro NK-cell mediated cytotoxicity.21-25 However, contrasting results 
have also been reported and suggested that in vitro, antigen-dependent activation of 
NKT cells is greater in the presence of LenDex than with dexamethasone alone.50 
While these findings have obvious clinical implications, it should also be noted that 
these studies have been mostly performed in vitro, using high-doses of 
dexamethasone, and in small patient series. In fact, very recent data has shown that 
PomDex can induce rapid activation of innate and adaptive immunity in heavily 
pretreated relapsed/refractory patients 51, which further contributes to the uncertainty 
about the potential antagonizing effect of dexamethasone in combination with IMiDs. 
Here, we had the unique opportunity to study T-lymphocytes and NK-cells from 
treatment-naïve high-risk SMM patients included in the Quiredex trial and exposed to 9 
induction cycles of lenalidomide plus low-dose dexamethasone 19, to elucidate whether 
or not the use of corticosteroids may have a detrimental effect on the immune 
modulatory activity of lenalidomide. Our results, based on longitudinal samples 
collected at baseline and after cycles 3 and 9 of LenDex, show a significant increase of 
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TCRγδ positive T-lymphocytes at cycle 3 coupled with a decrease of CD4 T-
lymphocytes at cycle 9. However, the most notorious differences in cellular distribution 
were noted for the distribution of T-lymphocyte antigen-related maturation subsets; the 
fact that CD4 and CD8 T-lymphocytes become enriched in central and effector memory 
cells after 3 and 9 cycles of LenDex identifies them as not yet terminally differentiated, 
which makes them promising candidates for anti-tumor response. Furthermore, it was 
interesting to observe that LenDex was able to restore the expression of those 
activation-, Th1- and proliferation-related markers that at baseline were found to be 
down-regulated in both CD4 and CD8 T-lymphocytes of high-risk SMM patients as 
compared to age-matched healthy individuals. CD56dim cytotoxic and CD56bright immune 
regulatory NK-cells were also found to be significantly activated after therapy. 
Accordingly, lenalidomide was able to effectively modulate the iPEP and proliferative-
rate of immune cells from high-risk SMM patients in the presence of dexamethasone; in 
fact, virtually no differences were observed in the number and iPEP of T-lymphocytes 
and NK-cells during maintenance therapy with lenalidomide and without concomitant 
dexamethasone. However, even though immune profiling was performed at least 3 
months after dexamethasone discontinuation, we cannot preclude long-lasting effects 
on the immune system of the 9 previous cycles with LenDex, and the optimal way to 
address this particular question (i.e.: abrogation of the immune modulation produced by 
lenalidomide with concomitant dexamethasone) would be in a randomized study 
comparing the immune profile of patients treated with LenDex vs. lenalidomide without 
dexamethasone. Furthermore, patients enrolled in the observation arm of the trial 
would have represented an important control group since this would allow us to 
investigate if the immune status of treatment-naive high-risk SMM patients may 
significantly vary in a period of approximately 1-year without any anti-myeloma therapy; 
unfortunately, such studies were not part of the original design of the trial. Similarly to 
what has been described in patients treated with LenDex 52,53 and PomDex 51, immune 
modulation of T-lymphocytes and NK-cells is possible albeit the expansion of Tregs. It 
could be hypothesized that such expansion is induced by dexamethasone, but Scott et 
al have most recently reported that that dexamethasone (alone or in combination 
lenalidomide) abrogated the ability of myeloma cell lines to induce Tregs expansion in 
vitro 54; alternately, increasing Treg numbers may reflect decreased TNFα levels after 
therapy that allow for Treg proliferation.55 That notwithstanding, we have not found 
significant differences in Treg numbers between patients in ≥VGPR vs. <VGPR (data 
not shown), similarly to that recently reported by Sehgal et al 51; accordingly, further 
translational research in IMiD/dex based clinical trials is warranted to fully understand 
the impact of each drug (separately and in combination) on Tregs. 
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 In summary, our results provide an immunologic rationale for the treatment of 
high-risk SMM patients with lenalidomide plus low-dose dexamethasone. Furthermore, 
the fact that a significant delay in TTP and consequent improvement in OS is being 
observed even among patients with residual disease after therapy, suggests potential 
immune surveillance of a reduced number of clonal PCs; accordingly, high-risk SMM 
patients progressing to symptomatic MM had significantly lower numbers of TCRγδ T-
lymphocytes. Our data, obtained from a carefully selected population of patients 
without previous exposure to anti-MM therapy and with available longitudinal samples 
after consecutive cycles of LenDex, shed new light on the synergism between 
lenalidomide and dexamethasone which, at low doses, does not abrogate the immune 
modulatory effects of lenalidomide. However, further studies are warranted to 
demonstrate an intrinsic relation between baseline versus lenalidomide-based immune 
cell activation and reduced risk of progression in high-risk SMM, particularly by using 
high-throughput protein and sequencing techniques not only to quantify immune 
effector cells, but also to determine their functionality and location within the tumor 
microenvironment.56 
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Table 1. Baseline demographic and clinical characteristics of the high-risk smoldering 
(SMM) patient population with available samples for immune profiling at baseline plus 
after 3 and 9 cycles of LenDex. 
Characteristic High-risk SMM patients (n=31) 
Age (years)  
     Median 59 
     Range 39 – 87 
Sex (no., %)  
     Male 14 (45%) 
     Female 17 (55%) 
Time since diagnosis (no., %)  
     ≤6 months 13 (42%) 
     >6 months 18 (58%) 
Criteria for high-risk SMM (no., %)  
     Mayo 6 (19%) 
     Pethema 12 (37%) 
     Both criteria 14 (44%) 
Serum M-component (g/dL)  
     Median 27 
     Range 7.6 – 56.6 
Urine M-component (g/24h)  
     Median 0 
     Range 0 – 1.5 
Bone marrow plasma cell infiltration (%)  
     Median 19 
     Range 10 - 48 
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Figure legends. 
Figure 1. Distribution of CD4, CD8, and TCRγδ T-lymphocytes as well as CD56dim and 
CD56bright NK-cells in peripheral blood (PB) samples from heathy individuals aged over 
60 years (n=10) and high-risk patients with smoldering multiple myeloma (SMM; n=31) 
studied at baseline, after 3 and 9 cycles of induction therapy with lenalidomide plus 
low-dose dexamethasone (LenDex) as assessed by multiparameter flow cytometry 
(MFC). The absolute counts (Nº cells/µL) are shown in Panel A, whereas the ratio 
between CD4 and CD8 T-lymphocytes as well as CD56dim and CD56bright NK-cells is 
shown in Panel B; distribution of antigen-maturation related subsets within total CD4 
and CD8 T-lymphocytes is represented in Panel C. In Panel D, the percentage of 
regulatory T-lymphocytes among nucleated PB cells is shown, whereas in Panel E the 
distribution of dendritic cells (DCs) and their plasmacytoid, BDCA-1 positive and 
negative plus tissue macrophage subsets in PB is represented. Bars represent median 
values and vertical lines the upper bound of the 95% confidence intervals. Notched 
boxes represent 25th and 75th percentile values; the line in the middle and vertical 
lines correspond to the median value and both the 10th and 90th percentiles, 
respectively. 
 
Figure 2. Detailed immunophenotypic features of CD4 and CD8 T-lymphocytes as well 
as CD56dim and CD56bright NK-cells in peripheral blood (PB) samples from heathy 
individuals aged over 60 years (n=10) and high-risk patients with smoldering multiple 
myeloma (SMM; n=31) studied at baseline, after 3 and 9 cycles of induction therapy 
with lenalidomide plus low-dose dexamethasone (LenDex) as regards to antigen 
expression of activation (Panel A) and Th1-related immune response markers (Panel 
B). Bars represent median values and vertical lines the upper bound of the 95% 
confidence intervals. 
 
Figure 3. Total percentage of proliferating S-phase T-lymphocytes and NK-cells in 
peripheral blood (PB) samples from heathy individuals aged over 60 years (n=10) and 
high-risk patients with smoldering multiple myeloma (SMM; n=31) studied at baseline, 
after 3 and 9 cycles of induction therapy with lenalidomide plus low-dose 
dexamethasone (LenDex). Each area represents the specific fluctuation of S-phase 
CD4 (light grey) and CD8 T-lymphocytes (grey) plus NK-cells (dark grey). 
 
Figure 4. Immunophenotypic protein expression profile (iPEP) of CD4 and CD8 T-
lymphocytes as well as CD56dim and CD56bright NK-cells in peripheral blood (PB) 
samples from high-risk patients with smoldering multiple myeloma (SMM; n=31) 
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studied at baseline, after 3 and 9 cycles of induction therapy with lenalidomide plus 
low-dose dexamethasone (LenDex). In Panel A, each of the 63 phenotypic parameters 
evaluated is distributed per individual columns, indicated in the bottom as “expression 
of the marker / immune cell population”, and is represented by color bars depicting 
normalized intensity values against that observed in heathy individuals aged over 60 
years (n=10), ranging from low (dark green) to high (dark red) expression levels. In 
Panel B principal component analysis (PCA) graphical view of patients’ iPEP. In the 
two-dimensional PCA representation, every patient is represented by a single dot 
colored according to the sample time point [baseline (orange), cycle 3 (blue) and 9 
(green) of LenDex], whereas in the three-dimensional PCA representation all patient 
samples were grouped according to their respective time-point. 
 
Figure 5. Fold-change expression of CD16 in CD56bright NK-cells, as well as IL-2 and 
CD195 in CD4 T-lymphocytes, from baseline to cycle 9 of induction therapy with 
lenalidomide plus low-dose dexamethasone (LenDex). High-risk SMM patients were 
grouped into those remaining assymptomatic (n=19) vs those progressing to 
symptomatic MM (n=12). Notched boxes represent 25th and 75th percentile values; the 
line in the middle and vertical lines correspond to the median value and both the 10th 
and 90th percentiles, respectively. 
 
Figure 6. Immunophenotypic protein expression profiles (iPEP) of CD4 and CD8 T-
lymphocytes as well as CD56dim and CD56bright NK-cells in peripheral blood (PB) 
samples from high-risk patients with smoldering multiple myeloma (SMM; n=13) 
studied after 9 cycles of induction therapy with lenalidomide plus low-dose 
dexamethasone (LenDex) vs. during maintenance with lenalidomide (at least three 
months after dexamethasone discontinuation). In the principal component analysis 
(PCA) graphical view, every patient is represented by a unique color, and iPEPs from 
PB samples studied after induction vs. during maintenance are represented by colored 
circles and squares, respectively.  
 
